<!doctype html>
<html class="no-js" lang="zxx">
<head>
   <meta charset="utf-8">
   <meta http-equiv="x-ua-compatible" content="ie=edge">
   <title> Illexcor-Leadership </title>
   <meta name="description" content="">
   <meta name="viewport" content="width=device-width, initial-scale=1">
   <link rel="shortcut icon" type="image/x-icon" href="img/favicon.png">

   <link rel="stylesheet" href="css/bootstrap.min.css">
   <link rel="stylesheet" href="css/style.css">
   <link rel="stylesheet" href="css/responsive.css">
</head>
<body>


<div class="page-loader">
   <span class="loader-3"></span>
</div>

<!-- header -->
<header class="header-area">
   <div id="header-sticky" class="menu-area">
      <div class="container">
         <nav class="navbar navbar-expand-lg">
            <a class="navbar-brand" href="index.html"><img src="img/logo.png" alt="logo"></a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarNavDropdown" aria-controls="navbarNavDropdown" aria-expanded="false">
               <span></span>
               <span></span>
               <span></span>
            </button>
            <div class="collapse navbar-collapse" id="navbarNavDropdown">
               <ul class="navbar-nav">
                  <li class="nav-item dropdown">
                     <a class="nav-link dropdown-toggle" href="company.html" role="button" data-bs-toggle="dropdown" aria-expanded="false">
                        Our Company
                     </a>
                     <ul class="dropdown-menu">
                        <li><a class="dropdown-item" href="about.html">About Us</a></li>
                        <li><a class="dropdown-item" href="leadership.html">Leadership</a></li>
                        <li><a class="dropdown-item" href="advisors.html">Advisors</a></li>
                        <!-- <li><a class="dropdown-item" href="collaborations.html">Collaborations</a></li> -->
                     </ul>
                  </li>
                  <li class="nav-item dropdown">
                     <a class="nav-link dropdown-toggle" href="science.html" role="button" data-bs-toggle="dropdown" aria-expanded="false">
                        Our Science
                     </a>
                     <ul class="dropdown-menu">
                        <li><a class="dropdown-item" href="pipeline.html">Pipeline</a></li>
                        <li><a class="dropdown-item" href="sickle.html">Sickle Cell Disease</a></li>
                        <li><a class="dropdown-item" href="lead.html">Our Lead</a></li>
                        <li><a class="dropdown-item" href="scientific.html">Scientific Publications</a></li>
                     </ul>
                  </li>
                  <li class="nav-item dropdown">
                     <a class="nav-link dropdown-toggle" href="opportunity.html" role="button" data-bs-toggle="dropdown" aria-expanded="false">
                        Our Opportunity
                     </a>
                     <ul class="dropdown-menu">
                        <li><a class="dropdown-item" href="overview.html">Overview</a></li>
                        <li><a class="dropdown-item" href="news.html">News and Events</a></li>
                        <li><a class="dropdown-item" href="investors.html">Investors</a></li>
                        <li><a class="dropdown-item" href="contact.html">Contact Us</a></li>
                     </ul>
                  </li>
                  <li class="nav-item"><a class="nav-link" href="news.html">News</a></li>
                  <li class="nav-item"><a class="nav-link" href="contact.html">Contact</a></li>
               </ul>
            </div>
         </nav>
      </div>
   </div>
</header>
<!-- header-end -->


<!-- main-area -->
<main>
   <section class="banner-area">
      <div class="banner-field inner-banner" style="background-image:url(img/banner/banner-1.webp);background-size:cover;">
         <div class="container">
            <div class="banner-content">
               <h2>Our Leadership</h2>
            </div>
         </div>
      </div>
   </section>

   <section class="submenu-area sticky-top">
      <div class="container">
         <div class="row justify-content-center">
            <div class="col-md-12 col-sm-12">
               <div class="menu-bar">
                  <a href="about.html">About Us</a>
                  <a href="leadership.html" class="active">Leadership</a>
                  <a href="advisors.html">Advisors</a>
                  <!-- <a href="collaborations.html">Collaborations</a> -->
               </div>
            </div>
         </div>
      </div>
   </section>


   <section class="inner-area thumbnails">
        <div class="container">
            <div class="row justify-content-center">
                <div class="col-md-3 col-sm-12">
                    <div class="thumbnail" id="thumbnail1">
                        <img src="img/leader/1.webp" alt="Image 1">
                        <div class="description">
                            <h3>Andrew Fleischman, MD</h3>
                            <h4>Chief Executive Officer</h4>
                            <a href="https://www.linkedin.com/in/andrew-fleischman-7a612b83/" target="_blank" class="linkedin">
                                 <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" viewBox="0 0 256 256"><path fill="#0a66c2" d="M218.123 218.127h-37.931v-59.403c0-14.165-.253-32.4-19.728-32.4c-19.756 0-22.779 15.434-22.779 31.369v60.43h-37.93V95.967h36.413v16.694h.51a39.907 39.907 0 0 1 35.928-19.733c38.445 0 45.533 25.288 45.533 58.186zM56.955 79.27c-12.157.002-22.014-9.852-22.016-22.009c-.002-12.157 9.851-22.014 22.008-22.016c12.157-.003 22.014 9.851 22.016 22.008A22.013 22.013 0 0 1 56.955 79.27m18.966 138.858H37.95V95.967h37.97zM237.033.018H18.89C8.58-.098.125 8.161-.001 18.471v219.053c.122 10.315 8.576 18.582 18.89 18.474h218.144c10.336.128 18.823-8.139 18.966-18.474V18.454c-.147-10.33-8.635-18.588-18.966-18.453"/></svg>
                            </a>
                            <p>
                                 Andrew N. Fleischman, MD is Co-Founder and Chief Executive Officer of Illexcor Therapeutics. Dr. Fleischman is a trained physician 
                                 and translational scientist who started his pursuit of innovative therapeutic and diagnostic technologies early in his career 
                                 even before completing residency training. Dr. Fleischman is now a seasoned executive and company builder with an instinct for 
                                 identifying promising technologies and rapidly advancing complex development programs with large teams. Dr. Fleischman led a
                                 team of medicinal chemists to discover new classes of Hemoglobin S polymerization inhibitors, including our lead drug ILX-002, 
                                 and is now leading the IND program and clinical program for ILX-002. In addition to leading Illexcor Therapeutics, Dr. Fleischman  
                                 has founded and built a rapidly growing in vitro diagnostics company CLEU Diagnostics and an innovative RNA-based medicines company 
                                 AmpedRNA Biosciences. Dr. Fleischman has a broad skill set, ranging from leading translational and clinical sciences to establishing 
                                 regulatory and intellectual property strategies for the company. Dr. Fleischman has brought in over $25 million in funding in the past 
                                 3 years for his companies, including more than $16 million in non-dilutive grants for innovative development programs. Dr. Fleischman 
                                 looks forward to advancing ILX-002 into the clinical and making his mark on patients across the world.
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-md-3 col-sm-12">
                    <div class="thumbnail" id="thumbnail2">
                        <img src="img/leader/2.webp" alt="Image 2">
                        <div class="description">
                            <h3>Martin Safo, PhD</h3>
                            <h4>Chief Scientific Officer</h4>
                            <a href="https://www.linkedin.com/in/martin-safo-b22ab13/" target="_blank" class="linkedin">
                              <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" viewBox="0 0 256 256"><path fill="#0a66c2" d="M218.123 218.127h-37.931v-59.403c0-14.165-.253-32.4-19.728-32.4c-19.756 0-22.779 15.434-22.779 31.369v60.43h-37.93V95.967h36.413v16.694h.51a39.907 39.907 0 0 1 35.928-19.733c38.445 0 45.533 25.288 45.533 58.186zM56.955 79.27c-12.157.002-22.014-9.852-22.016-22.009c-.002-12.157 9.851-22.014 22.008-22.016c12.157-.003 22.014 9.851 22.016 22.008A22.013 22.013 0 0 1 56.955 79.27m18.966 138.858H37.95V95.967h37.97zM237.033.018H18.89C8.58-.098.125 8.161-.001 18.471v219.053c.122 10.315 8.576 18.582 18.89 18.474h218.144c10.336.128 18.823-8.139 18.966-18.474V18.454c-.147-10.33-8.635-18.588-18.966-18.453"/></svg>
                           </a>
                            <p>
                                 Martin K. Safo, Ph.D. is Co-Founder and Chief Scientific Officer of Illexcor Therapeutics. Dr. Safo also directs the Center for 
                                 Drug Discovery as a highly distinguished Professor of Medicinal Chemistry at Virginia Commonwealth University. Dr. Safo is a 
                                 prolific scientist, with more than 160 published original research papers and 17 issued drug patents. Dr. Safo is a preeminent 
                                 international leader in the discovery of drugs for sickle cell disease, having spent three decades in the pursuit of highly 
                                 effective oral drugs to modify mutant Hemoglobin S. Along with his mentor the late Professor Donald Abraham, Dr. Safo’s pioneering 
                                 work on fundamental approaches to allosteric modification of hemoglobins led to a new era for the discovery of Hemoglobin S 
                                 polymerization inhibitors. This work was the basis for several clinical-stage drug candidates, including RSR-13 which was evaluated 
                                 as a Phase 3 anti-cancer agent by Allos Therapeutics and Aes-103, an oral drug for sickle cell disease that was acquired by Baxter 
                                 in 2014. As the culmination of three decades of scientific pursuit, ILX-002 is by far the most promising drug candidate discovered 
                                 by Dr. Safo, and he looks forward to bringing this therapy to patients in the US and throughout the world.
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-md-3 col-sm-12">
                    <div class="thumbnail" id="thumbnail3">
                        <img src="img/leader/3.webp" alt="Image 3">
                        <div class="description">
                            <h3>David Light, PhD</h3>
                            <h4>VP of R&D</h4>
                            <a href="https://www.linkedin.com/in/david-r-light-11755a5/" target="_blank" class="linkedin">
                              <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" viewBox="0 0 256 256"><path fill="#0a66c2" d="M218.123 218.127h-37.931v-59.403c0-14.165-.253-32.4-19.728-32.4c-19.756 0-22.779 15.434-22.779 31.369v60.43h-37.93V95.967h36.413v16.694h.51a39.907 39.907 0 0 1 35.928-19.733c38.445 0 45.533 25.288 45.533 58.186zM56.955 79.27c-12.157.002-22.014-9.852-22.016-22.009c-.002-12.157 9.851-22.014 22.008-22.016c12.157-.003 22.014 9.851 22.016 22.008A22.013 22.013 0 0 1 56.955 79.27m18.966 138.858H37.95V95.967h37.97zM237.033.018H18.89C8.58-.098.125 8.161-.001 18.471v219.053c.122 10.315 8.576 18.582 18.89 18.474h218.144c10.336.128 18.823-8.139 18.966-18.474V18.454c-.147-10.33-8.635-18.588-18.966-18.453"/></svg>
                           </a>
                            <p>
                                 David R. Light, Ph.D. has served as VP of Research & Development for Illexcor Therapeutics since 2020. This appointment followed a 
                                 productive decades-long career in the biopharmaceutical industry (Sanofi, Biogen, Bayer, Genentech, among others) in multiple 
                                 therapeutic areas, including hematology, cardiovascular, oncology, and immunology. Dr. Light’s efforts focusing on pre-clinical 
                                 development contributed to a number of INDs and several marketed drugs in benign hematology, such as Eloctate, Aprolix, and Cablivi. 
                                 While working at Berlex Biosciences/Schering AG, Dr. Light led the team that developed the Phase 1 benign hematology assets Solulin 
                                 (soluble thrombomodulin) and an oral factor Xa inhibitor, and a Phase 2 toxin-conjugated antibody for oncology (Anetumab). 
                                 After working on the pre-clinical discovery program for hemophilia at Bayer Healthcare, he joined Syntonix/Biogen Idec to develop 
                                 extended half-life clotting factors for hemophilia in 2011. In that same year, Dr. Light began a large sickle cell drug discovery 
                                 program at Biogen, which continued through 2020 at Bioverativ/Sanofi. He led large project teams on multiple therapeutic approaches 
                                 to treat sickle cell disease, including adhesion molecule inhibitors, oral drugs and cell-gene therapies to induce fetal hemoglobin 
                                 expression, and Hemoglobin S polymerization inhibitors. Dr. Light is excited about the promise of ILX-002 to deliver game-changing 
                                 results for patients with sickle cell disease.
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-md-3 col-sm-12">
                    <div class="thumbnail" id="thumbnail4">
                        <img src="img/leader/4.webp" alt="Image 4">
                        <div class="description">
                            <h3>Yash Shenoy, MBBA, MBA</h3>
                            <h4>Business Development</h4>
                            <a href="https://www.linkedin.com/in/yash-shenoy/" target="_blank" class="linkedin">
                              <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" viewBox="0 0 256 256"><path fill="#0a66c2" d="M218.123 218.127h-37.931v-59.403c0-14.165-.253-32.4-19.728-32.4c-19.756 0-22.779 15.434-22.779 31.369v60.43h-37.93V95.967h36.413v16.694h.51a39.907 39.907 0 0 1 35.928-19.733c38.445 0 45.533 25.288 45.533 58.186zM56.955 79.27c-12.157.002-22.014-9.852-22.016-22.009c-.002-12.157 9.851-22.014 22.008-22.016c12.157-.003 22.014 9.851 22.016 22.008A22.013 22.013 0 0 1 56.955 79.27m18.966 138.858H37.95V95.967h37.97zM237.033.018H18.89C8.58-.098.125 8.161-.001 18.471v219.053c.122 10.315 8.576 18.582 18.89 18.474h218.144c10.336.128 18.823-8.139 18.966-18.474V18.454c-.147-10.33-8.635-18.588-18.966-18.453"/></svg>
                           </a>
                            <p>
                                 Yash Shenoy, MBBS, MBA is a seasoned business development professional having closing over $500M in licensing and partnership 
                                 deals. He is a physician turned MBA originally from Hyderabad, India. Dr. Shenoy is passionate about identifying novel drug 
                                 development opportunities through Search & Evaluation and building win-win collaborative partnerships. In his previous role 
                                 as an investment manager at InvAscent, he led growth capital investments in early-stage companies in the healthcare and life 
                                 sciences sector in India. He helped close 13 investment deals with a total value over $100M. He also has served as Associate 
                                 Director of Business Development for Apollomics, a clinical stage oncology company. Dr. Shenoy was principal in in-licensing 
                                 5 key assets for the company.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

    <div id="modalimg" class="image-modal">
        <div class="modal-area">
            <span class="close">
                <svg xmlns="http://www.w3.org/2000/svg" width="42" height="42" viewBox="0 0 26 26"><g fill="#c60000"><path d="M9.854 16.854a.5.5 0 0 1-.708-.708l7-7a.5.5 0 0 1 .708.708z"/><path d="M9.146 9.854a.5.5 0 1 1 .708-.708l7 7a.5.5 0 0 1-.708.708z"/><path fill-rule="evenodd" d="M13 24.5c6.351 0 11.5-5.149 11.5-11.5S19.351 1.5 13 1.5S1.5 6.649 1.5 13S6.649 24.5 13 24.5m0 1c6.904 0 12.5-5.596 12.5-12.5S19.904.5 13 .5S.5 6.096.5 13S6.096 25.5 13 25.5" clip-rule="evenodd"/></g></svg>
            </span>
            <span class="prev">
                <svg xmlns="http://www.w3.org/2000/svg" width="52" height="52" viewBox="0 0 15 15"><path fill="none" stroke="#c60000" stroke-linecap="square" d="M10 14L3 7.5L10 1"/></svg>
            </span>
            <span class="next">
                <svg xmlns="http://www.w3.org/2000/svg" width="52" height="52" viewBox="0 0 15 15"><path fill="none" stroke="#c60000" stroke-linecap="square" d="m5 14l7-6.5L5 1"/></svg>
            </span>
            <div class="text-center">
               <img src="" alt="modal image" class="modalim-content">
               <div class="modal-description"></div>
            </div>
        </div>
    </div>
</main>
<!-- main-area-end -->


<!-- footer -->
<footer class="footer-area">
   <div class="container">
      <div class="row align-items-center justify-content-center">
         <div class="col-lg-3 col-12">
            <a class="footer-logo" href="index.html">
               <img src="img/logo.png" alt="logo">
            </a>
         </div>
         <div class="col-lg-6 col-12">
            <div class="copy-text text-center">
               Copyright 2024 Illexcor Therapeutics, LLC. All rights reserved. 
            </div>
         </div>
         <div class="col-lg-3 col-12">
            <div class="social">
               <a href="https://www.linkedin.com/company/illexcor-therapeutics-llc/" target="_blank">
                  <svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 24 24"><path fill="#fff" d="M20.47 2H3.53a1.45 1.45 0 0 0-1.47 1.43v17.14A1.45 1.45 0 0 0 3.53 22h16.94a1.45 1.45 0 0 0 1.47-1.43V3.43A1.45 1.45 0 0 0 20.47 2M8.09 18.74h-3v-9h3ZM6.59 8.48a1.56 1.56 0 1 1 0-3.12a1.57 1.57 0 1 1 0 3.12m12.32 10.26h-3v-4.83c0-1.21-.43-2-1.52-2A1.65 1.65 0 0 0 12.85 13a2 2 0 0 0-.1.73v5h-3v-9h3V11a3 3 0 0 1 2.71-1.5c2 0 3.45 1.29 3.45 4.06Z"/></svg>
               </a>
               <a href="https://twitter.com/illexcor" target="_blank">
                  <svg xmlns="http://www.w3.org/2000/svg" width="36" height="36" viewBox="0 0 448 512"><path fill="#fff" d="M64 32C28.7 32 0 60.7 0 96v320c0 35.3 28.7 64 64 64h320c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64zm297.1 84L257.3 234.6L379.4 396h-95.6L209 298.1L123.3 396H75.8l111-126.9L69.7 116h98l67.7 89.5l78.2-89.5zm-37.8 251.6L153.4 142.9h-28.3l171.8 224.7h26.3z"/></svg>
               </a>
            </div>
         </div>
      </div>
   </div>
</footer>

<a class="smoth-scroll" href="#top">
   <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" viewBox="0 0 24 24" {...$$props}>
      <path fill="#fff" d="m12 4l-.354-.354l.354-.353l.354.353zm.5 15a.5.5 0 0 1-1 0zM5.646 9.646l6-6l.708.708l-6 6zm6.708-6l6 6l-.708.708l-6-6zM12.5 4v15h-1V4z" />
   </svg>
</a>


<!-- JS here -->
<script src="js/jquery.min.js"></script>
<script src="js/bootstrap.bundle.min.js"></script>
<script src="js/main.js"></script>

</body>
</html>